生物加固吻合器与标准吻合器离断对远端胰腺切除术后胰瘘的影响:多中心随机临床试验
该多中心随机对照试验在瑞典四家三级转诊中心纳入107例拟行远端胰腺切除术的患者,术中随机分为生物加固吻合器离断组与标准吻合器离断组,患者对分组设盲。主要终点为任何术后胰瘘的发生。结果显示,临床相关胰瘘(B级和C级)在加固组为6/56(11%),标准组为8/50(16%),差异无统计学意义(P=0.332);总体并发症、住院时间两组亦无差异。结论:生物加固吻合器离断线并未减少远端胰腺切除术后胰瘘。
要点
- 生物加固吻合器离断未降低临床相关胰瘘(B/C级)发生率(11% vs 16%,P=0.332)。
- 总体并发症(80% vs 78%,P=0.765)与住院时间(中位8天 vs 9天,P=0.541)两组无差异。
- 远端胰腺切除术中常规使用生物加固吻合器离断胰腺不获益。
核心结论
- 与标准吻合器离断相比,胰腺离断线使用生物加固吻合器并未减少远端胰腺切除术后的术后胰瘘。
研究设计与样本
- 多中心随机对照试验,2014年5月至2016年2月在瑞典四家三级转诊中心开展。
- 拟行远端胰腺切除术的患者术中随机分为生物加固吻合器离断组或标准吻合器离断组,患者对分组设盲。
- 共107例随机,106例纳入意向性治疗分析(加固组56例,标准组50例)。
- 主要终点为任何术后胰瘘的发生;次要终点包括并发症、死亡率和住院时间。
主要发现
- 临床相关胰瘘(B级和C级):加固组6/56(11%),标准组8/50(16%),P=0.332。
- 总体术后并发症:加固组45例(80%),标准组39例(78%),P=0.765。
- 住院时间中位数:加固组8天(范围2-35),标准组9天(范围2-114),P=0.541。
临床怎么用
- 远端胰腺切除术中不推荐常规使用生物加固吻合器离断胰腺以预防术后胰瘘。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative pancreatic fistula is the leading cause of morbidity after distal pancreatectomy. Strategies investigated to reduce the incidence have been disappointing. Recent data showed a reduction in postoperative pancreatic fistula with the use of synthetic mesh reinforcement of the staple line. METHODS: An RCT was conducted between May 2014 and February 2016 at four tertiary referral centres in Sweden. Patients scheduled for distal pancreatectomy were eligible. Enrolled patients were randomized during surgery to stapler transection with biological reinforcement or standard stapler transection. Patients were blinded to the allocation. The primary endpoint was the development of any postoperative pancreatic fistula. Secondary endpoints included morbidity, mortality, and duration of hospital stay. RESULTS: Some 107 patients were randomized and 106 included in an intention-to-treat analysis (56 in reinforced stapling group, 50 in standard stapling group). No difference was demonstrated in terms of clinically relevant fistulas (grade B and C): 6 of 56 (11 per cent) with reinforced stapling versus 8 of 50 (16 per cent) with standard stapling (P = 0.332). There was no difference between groups in overall postoperative complications: 45 (80 per cent) and 39 (78 per cent) in reinforced and standard stapling groups respectively (P = 0.765). Duration of hospital stay was comparable: median 8 (range 2-35) and 9 (2-114) days respectively (P = 0.541). CONCLUSION: Biodegradable stapler reinforcement at the transection line of the pancreas did not reduce postoperative pancreatic fistula compared with regular stapler transection in distal pancreatectomy. Registration number: NCT02149446 (http://www.clinicaltrials.gov).
引用
- Wennerblom J, Ateeb Z, Jönsson C, et al. Reinforced versus standard stapler transection on postoperative pancreatic fistula in distal pancreatectomy: multicentre randomized clinical trial. Br J Surg. 2021. PMID: 33793753. doi:10.1093/bjs/znaa113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。